NCT05733286View on ClinicalTrials.gov

REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

June 28, 2023

Primary Completion Date

June 25, 2025

Study Completion Date

July 7, 2025

Conditions
Delirium in Old Age
Interventions
DRUG

Suvorexant 20 mg

Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2

DRUG

Placebo

Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Duke University

OTHER

NCT05733286 - REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant | Biotech Hunter | Biotech Hunter